HDAC9 and neoplasm: In vivo experiments further demonstrated that combining azacitidine with HDAC inhibitors, Entinostat or Givinostat, and anti-PD-1 resulted in the most substantial reduction in tumor burden, prolonged survival, and increased activated T and NK cell populations, while decreasing MDSCs [194].